⌘K
Loading ticker…
Zymeworks Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Zymeworks Inc. (ZYME) has a 3-month relative strength percentile of 36 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 57. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.8%, relative volume 1.35×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
36 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
ZYME is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $41M notional. Top 3 carry $82M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $41M |
| IWMiShares Russell 2000 ETF | 0.04% | $31M |
| IWOiShares Russell 2000 Growth ETF | 0.08% | $10M |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | 0.01% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ZYME Jan avg: 2.46% median: 2.03% win: 50% σ: 14.28% n: 4 2022-04-12 → 2026-05-29 | ZYME Feb avg: -1.77% median: -2.42% win: 50% σ: 10.84% n: 4 2022-04-12 → 2026-05-29 | ZYME Mar avg: -1.51% median: -1.80% win: 50% σ: 11.89% n: 4 2022-04-12 → 2026-05-29 | ZYME Apr avg: -1.16% median: 0.49% win: 60% σ: 11.92% n: 5 2022-04-12 → 2026-05-29 | ZYME May avg: -2.82% median: -2.02% win: 20% σ: 8.51% n: 5 2022-04-12 → 2026-05-29 | ZYME Jun avg: -1.50% median: 2.67% win: 75% σ: 13.64% n: 4 2022-04-12 → 2026-05-29 (current) | ZYME Jul avg: 4.88% median: 5.13% win: 75% σ: 15.49% n: 4 2022-04-12 → 2026-05-29 | ZYME Aug avg: 9.22% median: 10.95% win: 75% σ: 8.80% n: 4 2022-04-12 → 2026-05-29 | ZYME Sep avg: 1.46% median: 1.47% win: 50% σ: 12.20% n: 4 2022-04-12 → 2026-05-29 | ZYME Oct avg: 13.11% median: 11.23% win: 100% σ: 5.24% n: 4 2022-04-12 → 2026-05-29 | ZYME Nov avg: 18.26% median: 15.13% win: 100% σ: 18.07% n: 4 2022-04-12 → 2026-05-29 | ZYME Dec avg: 5.36% median: 2.86% win: 75% σ: 8.15% n: 4 2022-04-12 → 2026-05-29 |